Leiner to redistribute products
This article was originally published in The Tan Sheet
Executive Summary
FDA's Atlanta District Office grants Leiner Healthcare Products permission to begin distributing previously manufactured OTC products if a third-party quality assessment deems the products acceptable under FDA methodology. In an Oct. 22 Securities and Exchange Commission filing, the Carson, Calif.-based firm says it will begin re-distributing a portion of its inventory in December. Leiner suspended its U.S. OTC production and distribution March 20 and initiated a voluntary recall in April after FDA found GMP discrepancies at the firm's Fort Mill, S.C., facility (1"The Tan Sheet" Sept. 24. 2007, p. 12)
You may also be interested in...
Leiner’s Return To U.S. OTC Market Complicated By FDA Warning, DOJ Inquiry
FDA's investigation into manufacturing and quality control issues at Leiner Health Products' South Carolina facility revealed a culture of mismanagement that created a pattern of undetected production errors and overlooked discrepancies regarding product development, according to the agency
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.